CD8A and melanoma: However, while increased ALC early after the first dose and CD8+ T cell percentages later on (between 8 and 14 weeks of treatment) associated with improved survival and clinical response in melanoma patients, increased CD4+ T cell percentages at 8–14 weeks also correlated with these positive clinical outcomes (Martens et al., 2016).